Haematology A
IMDC Risk Model for Metastatic Renal Cell Carcinoma
International Metastatic RCC Database Consortium (IMDC) model. Predicts prognosis and guides first-line treatment selection in metastatic RCC.
References
- Heng DY et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27(34):5794-5799.
- Heng DY et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model. Lancet Oncol. 2013;14(2):141-148.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Fong Clinical Risk Score for CRC Liver Metastases · Cancer Prognosis
- FLIPI — Follicular Lymphoma International Prognostic Index · Cancer Prognosis
- CLL-IPI (International Prognostic Index for CLL) · Cancer Prognosis
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- WPSS — WHO Prognostic Scoring System for MDS · Cancer Prognosis
- MSKCC/Motzer Score for Metastatic RCC · Cancer Prognosis
Drugs
- Estradiol (HRT — Hormone Replacement Therapy) · Oestrogen Replacement Therapy
- Sodium Cromoglicate Nasal Spray · Mast Cell Stabiliser — Allergic Rhinitis
- Cetuximab · Anti-EGFR Monoclonal Antibody — Head and Neck Cancer
- Cisplatin · Platinum Chemotherapy — Head and Neck Cancer
- Olopatadine · H1 antihistamine + mast cell stabiliser
- Allopurinol · Xanthine Oxidase Inhibitor — Urate-lowering Therapy
Pathways
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO
Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.